An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline

Omadacycline is a once-daily oral or intravenous (i.v.) aminomethylcycline antibiotic approved in the United States for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. Omadacycline pharmacokinetics were charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovacs, Steven J., Ting, Lillian, Praestgaard, Jens, Sunkara, Gangadhar, Sun, Haiying, Stein, Daniel S., Tanaka, S. Ken, Villano, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577144/
https://www.ncbi.nlm.nih.gov/pubmed/32839218
http://dx.doi.org/10.1128/AAC.01650-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577144/
https://www.ncbi.nlm.nih.gov/pubmed/32839218
http://dx.doi.org/10.1128/AAC.01650-20

Ejemplares similares